论著

儿童幽门螺杆菌三联疗法根除疗效及影响因素分析

  • 耿甜 ,
  • 余仲苏 ,
  • 周西西 ,
  • 刘波 ,
  • 张慧华 ,
  • 李中跃
展开
  • 重庆医科大学附属儿童医院消化科 国家儿童健康与疾病临床医学研究中心 儿童发育疾病研究教育部重点实验室 儿童发育重大疾病国家国际科技合作基地 儿科学重庆市重点实验室(重庆 400014

收稿日期: 2022-04-26

  网络出版日期: 2024-01-05

基金资助

重庆市科卫联合医学科研项目(2019ZDXM045)

Analysis of eradication effect and influencing factors of triple therapy of Helicobacter pylori in children

  • Tian GENG ,
  • Zhongsu YU ,
  • Xixi ZHOU ,
  • Bo LIU ,
  • Huihua ZHANG ,
  • Zhongyue LI
Expand
  • Department of Gastroenterology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China

Received date: 2022-04-26

  Online published: 2024-01-05

摘要

目的 探索重庆地区儿童幽门螺杆菌(H.pylori)三联疗法根除疗效及影响因素。方法 收集消化科门诊就诊的156例疑似H.pylori感染儿童的胃黏膜标本,进行H.pylori培养、药敏试验和基因检测。H.pylori感染诊断明确的患儿接受三联疗法根除治疗,计算三联疗法根除率并分析疗效的影响因素。结果 156例疑似H.pylori感染儿童中符合H.pylori诊断标准的有138例,其中109例接受14天的标准三联方案(奥美拉唑+阿莫西林+克拉霉素)根除治疗,男53例、女56例,平均年龄(9.6±3.0)岁,最终64例(58.7%)根除成功。95例患儿H.pylori培养阳性,克拉霉素敏感株根除率81.6%(40/49)显著高于耐药株34.8%(16/46),差异有统计学意义(P<0.01)。95例患儿中87例行基因检测,根据基因检测结果克拉霉素敏感株根除率为76.2%(32/42),显著高于耐药株42.2%(19/45),差异有统计学意义(P<0.01)。患儿性别、年龄、内镜诊断、黏膜组织病理炎症程度、CYP2C19基因多态性、毒力基因vacAcagA与标准三联方案根除率无关(P>0.05)。结论 标准三联疗法不适合重庆地区儿童H.pylori治疗,以药敏试验为基础的个体化治疗方案是更好的选择。

本文引用格式

耿甜 , 余仲苏 , 周西西 , 刘波 , 张慧华 , 李中跃 . 儿童幽门螺杆菌三联疗法根除疗效及影响因素分析[J]. 临床儿科杂志, 2024 , 42(1) : 63 -69 . DOI: 10.12372/jcp.2024.22e0590

Abstract

Objective To explore the eradication effect and influencing factors of triple therapy of Helicobacter pylori (H.pylori) in children from Chongqing. Methods Gastric mucosa samples were collected from 156 children with suspected H.pylori infection who visited the gastroenterology clinic. H.pylori culture, drug susceptibility test and gene detection were performed. Children diagnosed with H.pylori infection received triple therapy eradication. The eradication rate of triple therapy was calculated and the influencing factors of efficacy were analyzed. Results Among 156 children with suspected H.pylori infection, 138 met the diagnostic criteria for H.pylori infection. Among them, 109 children (53 boys and 56 girls) were treated with standard triple therapy (omeprazole + amoxicillin + clarithromycin) for 14 days, with an average age of (9.6±3.0) years, and 64 (58.7%) were successfully eradicated from H.pylori infection. The eradication rate of clarithromycin sensitive strain was 81.6% (40/49), which was significantly higher than that of drug-resistant strain (34.8%, 16/46), the difference was statistically significant (P<0.01). Of the 95 children, 87 underwent genetic testing. The eradication rate of clarithromycin sensitive strains was 76.2% (32/42), which was significantly higher than that of drug-resistant strains (42.2%, 19/45), and the difference was statistically significant (P<0.01). Gender, age, endoscopic diagnosis, histopathological appearance of mucosal tissue based on severity of inflammation, CYP2C19 gene polymorphism, vacA and cagA virulence genes were not correlated with the eradication rate of standard triple regimen (P>0.05). Conclusions Standard triple therapy is not suitable for the eradication of H.pylori in children in Chongqing area, and individualized treatment based on drug sensitivity test is a better choice.

参考文献

[1] Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report[J]. Gut, 2017, 66(1): 6-30.
[2] Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016)[J]. J Pediatr Gastr Nutr, 2017, 64(6): 991-1003.
[3] Lee Y, Chiang T, Chou C, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis[J]. Gastroenterology, 2016, 150(5): 1113-1124.
[4] O'Connor A, Furuta T, Gisbert JP, et al. Review-treatment of Helicobacter pylori infection 2020[J]. Helicobacter, 2020, 25: e12743.
[5] 中华医学会儿科分会消化学组,《中华儿科杂志》编辑委员会. 儿童幽门螺杆菌感染诊治专家共识[J]. 中华儿科杂志, 2015, 3(7): 496-498.
[6] Wang B, Lv ZF, Wang YH, et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis[J]. World J Gastroentero, 2014, 20(40): 14973-14985.
[7] 李东丹, 周锦, 王国丽, 等. 儿童幽门螺杆菌耐药情况及影响因素分析[J]. 中华实用儿科临床杂志, 2019, 34(19): 1451-1453.
[8] 周颖, 王玉环, 芦军萍, 等. 上海市单中心儿童幽门螺杆菌不同治疗方案根除率及其耐药率的横断面调查[J]. 中国循证儿科杂志, 2019, 14(2): 81-86.
[9] 陈溢, 余金丹, 赵泓, 等. 儿童幽门螺杆菌感染根除治疗疗效分析[J]. 中国实用儿科杂志, 2018, 33(4): 291-296.
[10] Seo JH, Woo HO, Youn HS, et al. Antibiotics resistance of Helicobacter pylori and treatment modalities in children with H. pylori infection[J]. Korean J Pediatr, 2014, 57(2): 67-71.
[11] Masumi, Okuda, Shogo, et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan[J]. Pediatr Int, 2017. 59(1): 57-61.
[12] Kotilea K, Cadranel S, Salame A, et al. Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children[J]. Helicobacter, 2021, 26(4): e12825.
[13] Zhou Y, Ye Z, Wang Y, et al. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross﹕ ectional, comparative, open trial in Chinese children[J]. Helicobacter, 2020, 25(2): e12679.
[14] Savoldi A, Carrara E, Graham D Y, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization Regions[J]. Gastroenterology, 2018, 155(5):1372-1382.
[15] Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis[J]. Helicobacter, 2020, 25(4): e12692.
[16] Song Z, Zhou L, Xue Y, et al. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial[J]. Helicobacter, 2020, 25(6): e12762.
[17] Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection[J]. Clin Gastroenterol Hepatol, 2015, 13(5): 895-905.
[18] Li C, Shi Y, Suo B, et al. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: a systematic review and meta-analysis[J]. Helicobacter, 2021, 26(4): e12816.
[19] Sgouras D, Tegtmeyer N, Wessler S. Activity and functional importance of Helicobacter pylori virulence factors[J]. Adv Exp Med Biol, 2019, 1149: 35-56.
[20] Sharndama HC, Mba IE. Helicobacter pylori: An up-to-date overview on the virulence and pathogenesis mechanisms[J]. Braz J Microbiol, 2022, 53(1): 33-50.
[21] Wang D, Li Q, Gong Y, et al. The association between vacA or cagA status and eradication outcome of Helicobacter pylori infection: a meta-analysis[J]. PLoS One, 2017, 12(5): e0177455.
[22] Zhang SH, Zhu X, Li BM, et al. The effect of virulence genotypes of Helicobacter pylori on eradication therapy in children[J]. Saudi J Gastroenterol, 2018, 24(4): 249-254.
[23] López-Góngora S, Puig I, Calvet X, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection[J]. J Antimicrob Chemoth, 2015, 70(9): 2447-2455.
[24] Cosme A, Montes M, Ibarra B, et al. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance[J]. World J Gastroentero, 2017, 23(18): 3367-3373.
[25] Gong EJ, Ahn JY, Kim JM, et al. Genotypic and phenotypic resistance to clarithromycin in Helicobacter pylori strains[J]. J Clin Medicine, 2020, 9(6): 1930.
[26] 吕秋菊, 李秀英, 刘欢, 等. 中国人群中 CYP2C19 基因多态性对质子泵抑制剂三联疗法根除幽门螺杆菌疗效影响的meta分析[J]. 中国医院药学杂志, 2017, 37(11): 1097-1103.
[27] Arévalo Galvis A, Trespalacios Rangel AA, Otero Regino W. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy[J]. Helicobacter, 2019, 24(3): e12574.
[28] Graham DY, Dore MP. Update on the use of vonoprazan: a competitive acid blocker[J]. Gastroenterology, 2018, 154(3): 462-466.
[29] Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phaseⅢ, randomised, double-blind study[J]. Gut, 2016, 65(9): 1439-1446.
[30] Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori[J]. Helicobacter, 2018, 23(4): e12495.
文章导航

/